Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

[1]  Lei Lu,et al.  Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs , 2014, Journal of Translational Medicine.

[2]  Shulan Zhang,et al.  Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer , 2013, Journal of Translational Medicine.

[3]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[4]  Q. Feng,et al.  Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation , 2013, Journal of immunotherapy.

[5]  Sheng Yao,et al.  Advances in targeting cell surface signalling molecules for immune modulation , 2013, Nature Reviews Drug Discovery.

[6]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[7]  T. Daemen,et al.  Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. , 2012, Current pharmaceutical design.

[8]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[9]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[10]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[11]  K. Hellström,et al.  Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. , 2012, Gynecologic oncology.

[12]  E. Swisher,et al.  Silencing of the TGF-&bgr;1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma , 2012, Journal of immunotherapy.

[13]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[14]  C. Drake,et al.  Immunotherapy earns its spot in the ranks of cancer therapy , 2012, The Journal of experimental medicine.

[15]  J. Allison,et al.  Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.

[16]  G. Coukos,et al.  Immunotherapy for ovarian cancer: what's next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Wolchok,et al.  Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation , 2010, PloS one.

[18]  T. Eberlein,et al.  Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer , 2009, Clinical Cancer Research.

[19]  A. Gewirtz,et al.  Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. , 2009, The Journal of clinical investigation.

[20]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[21]  S. Morrison,et al.  Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity , 2009, Cancer Immunology, Immunotherapy.

[22]  S. Kang,et al.  Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. , 2008, Cancer research.

[23]  L. Khawli,et al.  Construction and Preclinical Characterization of Fc-mGITRL for the Immunotherapy of Cancer , 2008, Clinical Cancer Research.

[24]  P. Zhou,et al.  Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors , 2007, The Journal of Immunology.

[25]  W. Gong,et al.  Soluble PD-1 Facilitates 4-1BBL–Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo , 2007, Clinical Cancer Research.

[26]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[27]  M. V. D. van den Brink,et al.  Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity1 , 2006, The Journal of Immunology.

[28]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[29]  Mitchell Ho,et al.  Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients , 2005, Clinical Cancer Research.

[30]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[31]  Ethan M. Shevach,et al.  Engagement of Glucocorticoid-Induced TNFR Family-Related Receptor on Effector T Cells by its Ligand Mediates Resistance to Suppression by CD4+CD25+ T Cells , 2004, The Journal of Immunology.

[32]  L. Karns,et al.  Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. , 2003, International immunology.

[33]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[34]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[36]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[37]  G. Parham,et al.  Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer , 2001, Gynecologic and Obstetric Investigation.

[38]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[40]  U. Göhring,et al.  Immunologic Features of Tumor-Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Overian Cancer Patients , 1998, The Journal of the Society for Gynecologic Investigation: JSGI.

[41]  L. Brandes,et al.  IMMUNOTHERAPY FOR OVARIAN CANCER , 1976, The Lancet.